Amgen Drug Shows Positive Results in Late-Phase Study
A late-phase clinical study of Amgen Inc.’s experimental treatment for secondary hyperparathyroidism in patients with chronic kidney disease showed a higher percentage of patients responded to its treatment.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news
More News: Chronic Kidney Disease | Health | Hyperparathyroidism | Pharmaceuticals | Study | Urology & Nephrology